Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part I.
Preskorn
Sheldon H
SH
Department of Psychiatry, University of Kansas School of Medicine-Wichita, KS, USA.
Borges
Silvana
S
Flockhart
David
D
D000077443:Acamprosate; D000427:Alcohol Deterrents / Q000627:therapeutic use*; D000437:Alcoholism / Q000188:drug therapy*; D000544:Alzheimer Disease / Q000188:drug therapy*; D001921:Brain / Q000503:physiopathology*; D015259:Dopamine Agents / Q000627:therapeutic use*; D006801:Humans; D008559:Memantine / Q000627:therapeutic use*; D001523:Mental Disorders / Q000188:drug therapy* / Q000503:physiopathology*; D011619:Psychotropic Drugs / Q000145:classification* / Q000627:therapeutic use; D013654:Taurine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000427:Alcohol Deterrents; D015259:Dopamine Agents; D011619:Psychotropic Drugs; D013654:Taurine; D000077443:Acamprosate; D008559:Memantine